LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Fermé

SecteurSoins de santé

15.05 -1.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.96

Max

15.32

Chiffres clés

By Trading Economics

Revenu

1.8B

16B

Ventes

1.5B

85B

P/E

Moyenne du Secteur

19.628

50.291

BPA

19.11

Rendement du dividende

0.62

Marge bénéficiaire

18.66

Employés

27,811

EBITDA

985M

25B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.24% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.62%

2.40%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

10B

13B

Ouverture précédente

16.81

Clôture précédente

15.05

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 mai 2025, 18:56 UTC

Résultats

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 mai 2025, 18:56 UTC

Résultats

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

23 janv. 2025, 17:46 UTC

Résultats

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 janv. 2025, 17:42 UTC

Résultats

Dr. Reddy's 3Q Rev INR83.59B

5 nov. 2024, 11:01 UTC

Résultats

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov. 2024, 11:00 UTC

Résultats

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov. 2024, 10:57 UTC

Résultats

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov. 2024, 10:57 UTC

Résultats

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Comparaison

Variation de prix

Dr Reddy's Laboratories Ltd-ADR prévision

Objectif de Prix

By TipRanks

10.24% hausse

Prévisions sur 12 Mois

Moyen 16.9 USD  10.24%

Haut 16.9 USD

Bas 16.9 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 13.84Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.